After the US Food and Drug Administration approval in 2002 of the first ever fully human mAb drug (AbbVie’s Humira (adalimumab)), fully human mAbs rapidly became the gold standard of mAb-based ...
I-Mab Biopharma (‘I-Mab’), headquartered in Shanghai, is different. From its inception in 2015, the company has been focused exclusively on discovering and developing innovative biologics ...
人与生物圈计划（MAB）属于政府间科学计划，旨在为加强人与环境之间的关系奠定科学基础。它结合自然科学与社会科学，寻求改善人类生计并保护自然和人工的生态系统，从而以适宜社会与 ...
Aug. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the ...
ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback